Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database

Published:2024-07-10 Issue: Volume: Page:1-11
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Wan Xiaochen¹,Zhang Shuohan²³,Jiang Cheng²³^ORCID,Zhang Hongrui¹

Affiliation:

1. Department of Clinical Laboratory, Zhejiang Hospital, Hangzhou, Zhejiang, China

2. Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China

3. School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China

Funder

Public Service Technology Research Project of Zhejiang Province

National Natural Science Foundation of China

Medical Health Science and Technology Project of Zhejiang Province

State Administration of Traditional Chinese Medicine Science

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2024.2371382

Reference53 articles.

1. Migraine overview and summary of current and emerging treatment options;Peters GL.;Am J Manag Care,2019

2. Migraine

3. Pharmacokinetics and pharmacodynamics of new acute treatments for migraine

4. The physiopathology of migraine: the contribution of genetics

5. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP